Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytogen gets FDA approval for product licence application (PLA) supplement:

This article was originally published in Clinica

Executive Summary

The US FDA has approved Cytogen's PLA supplement for its OncoScint CR/OV, expanding the imaging agent's indications to include readministration to HAMA-negative patients at risk of cancer recurrence. OncoScint received FDA approval in December 1992 and is the only such agent approved for tumour imaging, claims Cytogen. There have been around 150,000 cases of colorectal cancer each year in the US since 1990, according to the American Cancer Society.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts